3상모집 중단 (진행 중)
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
연구 개요
This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with at least a BTK inhibitor. The main purpose is to compare LOXO-305 to idelalisib plus rituximab or bendamustine plus rituximab. Participation could last up to four years, and possibly longer, if the disease does not progress.
- 스폰서
- 협력: 일라이 릴리
- 적응증
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- 중재
- Pirtobrutinib, Idelalisib, Bendamustine, Rituximab
- 목표 등록
- 238명
- 시작일
- 2021-03-09
- 완료(예정)
- 2027-05-01
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.